GENE ONLINE|News &
Opinion
Blog

2021-04-14| Trials & Approvals

Novartis, Genentech Bag Key FDA Okay for Blockbuster Drug

by Rajaneesh K. Gopinath
Share To

Novartis and Genentech have won a key FDA approval that could help their blockbuster drug, Xolair gain a few paces ahead of its competitors. On April 13th, the companies announced that the FDA has approved their supplemental BLA for Xolair prefilled syringe for self-injection.

Xolair (omalizumab) is an IgE targeting monoclonal antibody that reduces allergic symptoms. It is FDA-approved for three major indications; moderate-to-severe Asthma, Chronic Idiopathic Urticaria (CIU), and Nasal Polyps. Currently, it is the only FDA-approved biologic designed to target and block IgE for treating these indications. First launched as a sterile lyophilized powder that had to be reconstituted for injection, Xolair gained FDA approval for prefilled syringe formulation in 2018. Prior to the latest approval for self-injection, the drug could be administered only in a healthcare setting by a licensed provider.

Only patients who do not have a prior history of anaphylaxis and have received at least three injections of Xolair by a provider without exhibiting allergic reactions could be eligible for self-injection. As per FDA guidelines, the drug treatment must be initiated and safely established in a healthcare setting, following which a provider can recommend self-injection either by the patient themselves or a caregiver.

“Today’s FDA approval represents an important milestone for Xolair and highlights our continued commitment to innovation for patients since its first approval in 2003,” said Victor Bultó, President, Novartis Pharmaceuticals Corporation. “With the new offering of self-injection for Xolair, healthcare providers now have an additional administration option for appropriate patients, which is particularly timely given the COVID-19 pandemic.”

 

Competition

Xolair is a blockbuster drug that currently faces stiff competition from Sanofi and Regeneron’s Dupixent in two indications and counting. Besides, a number of Xolair biosimilars are in the pipeline, namely Glenmark Pharmaceuticals’ GBR 310, Sorrento Therapeutics/MabTech’s STI-004, Celltrion Healthcare’s CT-P39, and BiosanaPharma’s BP001. The regulatory win for self-injection will give Novartis and Genentech a slight advantage from the contest.

To deal with the competition, Novartis is advancing a much potent anti-IgE monoclonal antibody, ligelizumab, an asset it acquired from Ziarco Group Limited. Ligelizumab has already bagged the FDA’s breakthrough therapy designation for treating CIU. For its part, Genentech, a Roche subsidiary, is also evaluating Fenebrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) in CIU.

“Today’s approval reflects our commitment to continued innovation with Xolair to address the critical needs of people living with allergic and inflammatory conditions,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer, and Head of Global Product Development. “Appropriate patients will now have the flexibility to administer Xolair from home, which is particularly important for those who are considered high-risk during the COVID-19 pandemic.”

Related Article: Gilead’s Breast Cancer Drug that Came off a $21 Billion Buyout Finally Gets FDA’s Full Approval

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Novartis Secures Approval for First-Ever Malaria Treatment Designed for Newborns After a Decade of Research
2025-07-09
What’s Next for Emerging Biotechs? Investment and R&D Insights from BIO 2025
2025-06-18
Psychedelics Are Driving a Mental Health Revolution with Long-Lasting Therapeutic Potential
2025-06-17
LATEST
Air Pollution, Inequality, and Weak Democracies Linked to Faster Aging in Global Study
2025-07-14
Analysis Reveals Publication Bias in Scientific Research Dates Back to Modern Science’s Origins
2025-07-14
Oncology Pharmacists Tackle Biosimilar Integration and 505(b)(2) Drug Adoption at ATOPP 2025 Conference
2025-07-14
Pneumococcal Vaccination Linked to Lower Risk of Severe COVID-19 Outcomes in Patients with Inflammatory Rheumatic Diseases
2025-07-14
Finnish Study Finds Brain Biomarkers for Alzheimer’s Detectable in Middle Age
2025-07-14
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
University of Tokyo Researchers Develop In Vivo System to Study Senescent Cells in Aging
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top